A RESPONSE TO: 'COST-EFFECTIVENESS OF ORAL SEMAGLUTIDE ADDED TO CURRENT ANTIHYPERGLYCEMIC TREATMENT FOR TYPE 2 DIABETES'
| Autor: | Amy Beal, Brandon K. Bellows, Natalia Ruiz-Negrón, Ciaran N. Kohli-Lynch |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
business.industry Cost effectiveness Cost-Benefit Analysis Health Policy Semaglutide Glucagon-Like Peptides MEDLINE Pharmaceutical Science Pharmacy Type 2 diabetes medicine.disease Diabetes Mellitus Type 2 medicine Humans Hypoglycemic Agents Current (fluid) Intensive care medicine business |
| Zdroj: | Journal of Managed Care & Specialty Pharmacy. 27:1140-1141 |
| ISSN: | 2376-1032 2376-0540 |
| DOI: | 10.18553/jmcp.2021.27.8.1140 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|